The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1).
 
Alexander E. Drilon
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Genentech/Roche; Ignyta; Loxo; Pfizer; Takeda; TP Therapeutics
 
Sai-Hong Ignatius Ou
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - ARIAD/Takeda; AstraZeneca; Foundation Medicine; Genentech/Roche; Novartis; Pfizer; Roche Pharma AG
Consulting or Advisory Role - AstraZeneca; Foundation Medicine; Ignyta; Novartis; Pfizer; Roche/Genentech; Takeda; TP Therapeutics
Speakers' Bureau - AstraZeneca; Genentech; Takeda
Research Funding - ARIAD (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Ignyta (Inst); Peregrine Pharmaceuticals (Inst); Pfizer (Inst); Roche Pharma AG (Inst)
 
Byoung Chul Cho
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; Novartis; Roche; Yuhan
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck KGaA; Novartis; Roche; Yuhan
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck; Novartis
Research Funding - AstraZeneca; Bayer; Novartis; Yuhan
 
Dong-Wan Kim
No Relationships to Disclose
 
Jeeyun Lee
No Relationships to Disclose
 
Jessica Jiyeong Lin
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim
 
Viola Weijia Zhu
Stock and Other Ownership Interests - TP Therapeutics (I)
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Bayer; Biocept; TP Therapeutics
Speakers' Bureau - AstraZeneca; Roche/Genentech; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Roche Molecular Diagnostics; Roche/Genentech; Takeda; TP Therapeutics
 
HyeRyun Kim
No Relationships to Disclose
 
Tae Min Kim
No Relationships to Disclose
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly; MSD
 
D. Ross Camidge
Honoraria - AstraZeneca; bio-thera; Daiichi Sankyo; G1 therapeutics; Genoptix; Hansoh; Ignyta; Lycera; Mersana; Revolution Medicines; Roche; takeda
Research Funding - Takeda
 
John K.C. Lim
Employment - TP Therapeutics
Stock and Other Ownership Interests - Senhwa Biosciences
Consulting or Advisory Role - Senhwa Biosciences
 
Shanna Stopatschinskaja
Employment - TP Therapeutics
Stock and Other Ownership Interests - TP Therapeutics
 
Jingrong Jean Cui
Employment - TP Therapeutics
Leadership - TP Therapeutics
Stock and Other Ownership Interests - TP Therapeutics
Patents, Royalties, Other Intellectual Property - TP Therapeutics
 
David Michael Hyman
Consulting or Advisory Role - ArQule; AstraZeneca; Atara Biotherapeutics; Bayer; Boehringer Ingelheim; Chugai Pharma; CytomX Therapeutics; Debiopharm Group; Genentech; Pfizer
Research Funding - AstraZeneca; Loxo; Puma Biotechnology
 
Robert Charles Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Honoraria - ARIAD; AstraZeneca; Guardant Health; Pfizer; Spectrum Pharmaceuticals; Takeda; Trovagene
Consulting or Advisory Role - AstraZeneca; GreenPeptide; Ignyta; OncoMed; Pfizer; Trovagene
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - ARIAD; Guardant Health; Ignyta
 
Alice Tsang Shaw
Honoraria - Foundation medicine; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Daiichi Sankyo; EMD Serono; Genentech; Ignyta; KSQ Therapeutics; Loxo; Natera; Novartis; Pfizer; Roche; Taiho Pharmaceutical; Takeda
Research Funding - Novartis; Pfizer; Roche/Genentech